Houstonian Lindsay Huelse launched the number one wellness app for women.Photo courtesy of The FITT Cycle

Sticking to a fitness routine can be challenging — what with the myriad exercises, personal trainers, gyms, and apps. Creating a personalized program to fit specific goals, gain confidence, and take control of health concerns is what drove Houstonian Lindsay Huelse to launch a wildly popular female wellness app.

The FITT Cycle (which stands for Fasting, Intervals, and Target Training) app incorporates fitness routines, nutrition plans, accountability, community, and entrepreneurship.

"Historically, fitness apps are great for memberships," Huelse tells CultureMap. "I wanted to create a platform for returning clients where they could have stability and ditch the diets."

Since its launch in December 2019, Huelse says she has seen a membership growth of almost 2,000 percent, noting that there is no other app with The FITT Cycle's features. She calls it a hybrid of My Fitness Pal, the Peloton App, Facebook communities, and more.

"Everything is in one place," she adds.

The app combines exercise and diet to make for a more complete health tracking app than existing technology. Photo courtesy of The FITT Cycle

A retired nurse, Huelse is now a certified nutrition coach and self-proclaimed "queen of carb cycling," a regimen that focuses on alternating daily carbohydrate intake to promote weight loss and overcome weight loss plateaus.

Fitness has always played a role in Huelse's life, both on and off the field. She played soccer competitively throughout high school and college but it wasn't until her pre-nursing track where she became intrigued by nutrition.

"It was something I didn't learn growing up," Huelse adds. "I was fascinated with fueling my body to help it function properly."

Upon graduation, she worked in the intensive care unit before retiring in 2018 from the corporate world of home health and hospice. As a geriatric nurse, she says she enjoyed educating the elderly on manageable ways to change their diet and reduce inflammation, something they're not always willing to do.

"This led me to be passionate about helping women with preventative measures to decrease inflammation and create food freedom," she says.

With multiple features, including carb cycling macros and an in-app nutrition tracker for weight loss success; daily workouts and targeted training for the home or gym; an in-app guide to intermittent fasting with a timer to indicate when the fasting window is complete; a community to keep members accountable; and a library of more than 250 recipes, The FITT Cycle app is truly customizable for your health, wellness, and fitness goals.

"As a woman who used to work out for hours at a time and follow a clean nutrition plan, I was gaining weight but couldn't understand why," she says. "There's a science to reaching your fitness goals and through learning about my clients who have children, are older, or are postmenopausal helped me design the app to show them you don't have to feel fatigued or struggle with losing weight."

Huelse adds that the last diet her clients followed will be the last diet they ever chase.

Every one of Huelse's clients who join The FITT Cycle app has the opportunity to earn a 50 percent commission for anyone they enroll in the app. Huelse says her vision for creating a cycle of entrepreneurship is to give back to her community and to those who helped her on her path to entrepreneurship.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.